Stride boasts strong financials, with a 14% revenue CAGR and a 33% adjusted operating income CAGR over the past two years.

Akebia Therapeutics' Vafseo expansion may boost future growth despite Auryxia's exclusivity loss. Read why AKBA stock is ...